FDA Law Blog: Biosimilars

JUNE 12, 2024

Our ideal candidate will have significant substantive experience working with: Price calculation and reporting under the Medicaid Drug Rebate Program and the 340B Drug Discount Program Average sales price reporting under Medicare Part B Price reporting and contracting with the Department of Veterans Affairs Drug discounting requirements under the Inflation (..)

Department of Veterans Affairs 59

Department of Veterans Affairs 59

PharmaState Academy

MAY 1, 2023

Department of Veterans Affairs found that “patients’ health outcomes improve when physicians individualize care and take their patients’ life circumstances into account.” In the coming age of biopharmaceuticals and biosimilars, every patient will have different needs, especially young patients with life-style disease problems.

Department of Veterans Affairs 52

Department of Veterans Affairs Communication Hospitals Biosimilars 52

Putting Patients First Blog

JANUARY 27, 2025

AOMs are already covered under various other insurance programs, including the Federal Employees Health Benefits Program, Medicaid, the Department of Veterans Affairs, TRICARE, commercial insurance plans, and state employee health plans. 2 Effective management requires a comprehensive approach.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

FDA Law Blog: Biosimilars

MAY 12, 2025

What types of drugs are to be covered: brands, generics, biologics, biosimilars, or some combination? MFN pricing reemerged in todays Executive Order, which goes well beyond the 2020 order. How will MFN targets be determined by HHS and for how many drugs?

Department of Veterans Affairs 64

Department of Veterans Affairs Drug Pricing Pharmaceutical Manufacturing Biosimilars 64